Coronary disease & ACSCohort study
Medication persistence and mortality in ST-elevation myocardial infarction patients with and without standard modifiable risk factors: a SWEDEHEART registry study
- Registry-based cohort study
- landmark analysis
- population-level
Authors' conclusion
Persistence with secondary prevention medication declined rapidly in this cohort.
Study context
- Population
- First-time ST-elevation myocardial infarction (STEMI) patients prescribed aspirin, lipid-lowering therapy, renin-angiotensin-aldosterone system (RAAS) inhibitors or beta-blockers at discharge, SWEDEHEART registry
- Participants
- 65,059 patients
- Exposure
- Medication non-persistence vs persistence at 12 months, in SMuRF-less vs SMuRF-positive STEMI patients
- Outcome
- All-cause mortality
- Follow-up
- 3 years after the 12-month landmark
Main finding
As reported in the abstract
All-cause mortality by 12-month non-persistence · 3 years after landmark
Discontinuing aspirin, lipid-lowering therapy (LLT) or RAAS inhibitors within 12 months associated with increased mortality in both groups (HR range)
1.45 and 2.02
Observational data: associations, not effects.
Further findings
Discontinuation at 4 years after initiation
- Patients who had discontinued aspirin, LLT, RAAS inhibitor or beta-blocker
- >50%
Prescription at discharge and 12-month persistence
- SMuRF-less less likely to receive medications at discharge; if prescribed, more likely persistent with aspirin and LLT vs SMuRF-positive
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Medication persistence and mortality in ST-elevation myocardial infarction patients with and without standard modifiable risk factors: a SWEDEHEART registry study. Eur J Prev Cardiol. Published 1 September 2026. doi:10.1093/eurjpc/zwag421
Summarised from the published abstract; every number is checked against it